The DYDC1 Knockout HAP1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population for targeted DYDC1 gene disruption in a human near-haploid background. This loss-of-function model permits investigation of DYDC1 biology without confounding allele complementation typical of diploid lines. The polyclonal format harbors a heterogeneous knockout genotype pool, making it suitable for pooled genetic screens and gene essentiality analyses.
HAP1 cells are a human near-haploid fibroblastoid line derived from KBM-7 chronic myeloid leukemia cells. Their haploid karyotype simplifies knockout phenotype analysis because a single gene disruption can yield complete inactivation. These adherent, immortalized cells maintain relevant signaling and epigenetic machinery, offering a robust system for chromatin and transcription studies.
DYDC1 is a putative scaffold or regulatory component of COMPASS/Set1-like histone H3K4 methyltransferase complexes. It is predicted to interact with core factors ASH2L, RBBP5, WDR5, DPY30, and MLL family methyltransferases to promote H3K4 methylation at promoters of active genes, including HOX clusters and cell cycle regulators. DYDC1 may function downstream of oncogenic signals such as MYC and developmental pathways, integrating extracellular cues to epigenetic and transcriptional outputs. Disruption of DYDC1 is expected to reduce H3K4 methylation and alter gene expression profiles impacting proliferation and differentiation.
HAP1 cells, originating from a leukemic line, provide a relevant background for studying DYDC1’s role in cancer-related H3K4 methylation dynamics. The haploid state eliminates allele heterogeneity, enabling clear interpretation of knockout phenotypes. This model can assess DYDC1’s contribution to leukemic cell maintenance and epigenetic drug sensitivity. Moreover, the polyclonal population supports synthetic lethality screens to identify genetic dependencies that arise upon DYDC1 loss.
Researchers can utilize this product for western blotting of H3K4me1/2/3, ChIP-seq to map DYDC1-dependent genomic loci, and RNA-seq for transcriptome profiling. Targeted gene validation via RT-qPCR and proliferation or drug sensitivity assays with histone methyltransferase inhibitors are direct applications. The DYDC1 Knockout HAP1 Polyclonal Cells serve as a versatile tool for chromatin biology, cancer epigenetics, synthetic lethality screening, and drug target discovery. For additional information, please contact Ascent Research.
